MedTrace Logo

The Management of Work-Disability Associated With Co-Morbid Pain and Depression: A Feasibility Study

NCT05174429 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-12-30

No results posted yet for this study

Summary

The purpose of the present study was to conduct a preliminary evaluation the feasibility and impact of a risk-targeted behavioral activation intervention for work-disabled individuals with co-morbid pain and depression.

Conditions

Interventions

BEHAVIORAL

Risk-Targeted Behavioral Activation

The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire. Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence.

Sponsors & Collaborators

  • l'Institut de recherche Robert-Sauvé en santé et en sécurité du travail (IRSST)

    collaborator UNKNOWN

  • McGill University

    lead OTHER

Principal Investigators

  • Michael Sullivan, PhD · McGill University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-10
Primary Completion
2018-10-20
Completion
2018-12-15

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05174429 on ClinicalTrials.gov